Additionally, we observed that pre-treatment AML patients with serum BAFF values higher than the median (3,615.14 pg/ml) had a significantly shorter overall survival (OS) than patients with a lower BAFF value, p = 0.03 (Fig. 1). Here, TNFSF13B is linked to acute myeloid leukemia.